Ambrx Biopharma Return on Equity

Ambrx Biopharma (AMAM) currently reports a ROE of -28.62%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Ambrx Biopharma's ROE history and peer comparisons.

Ambrx Biopharma's ROE of -28.62% is lower than the Healthcare sector average of 29.33%. That is roughly 197.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Ambrx Biopharma's current -28.62% should be judged against Healthcare norms (sector average: 29.33%) and against AMAM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -28.62%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Ambrx Biopharma, and consider following AMAM for alerts when major investors trade the stock.

Ambrx Biopharma is classified in the Healthcare sector. On ROE, it currently shows -28.62% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing AMAM with unrelated industries.